Rifampin Use and Safety in Hospitalized Infants

 

 Buy Article Permissions and Reprints

Abstract

Objective This study aims to examine the use and safety of rifampin in the hospitalized infants.

Study Design Observational study of clinical and laboratory adverse events among infants exposed to rifampin from 348 neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2012.

Result Overall, 2,500 infants received 4,279 courses of rifampin; mean gestational age was 27 weeks (5th, 95th percentile; 23, 36) and mean birth weight was 1,125 g (515; 2,830). Thrombocytopenia (121/1,000 infant days) and conjugated hyperbilirubinemia (25/1,000 infant days) were the most common laboratory adverse events. The most common clinical adverse events were medical necrotizing enterocolitis (64/2,500 infants, 3%) and seizure (60/2,500 infants, 2%).

Conclusion The overall incidence of adverse events among infants receiving rifampin appears low; however, additional studies to further evaluate safety and dosing of rifampin in this population are needed.

^* Katherine Y. Berezny, Duke Clinical Research Institute, Durham, NC; Edmund Capparelli, University of California–San Diego, San Diego, CA; Michael Cohen-Wolkowiez, Duke Clinical Research Institute, Durham, NC; Gregory L. Kearns, Children's Mercy Hospital, Kansas City, MO; Matthew Laughon, University of North Carolina at Chapel Hill, Chapel Hill, NC; Andre Muelenaer, Virginia Tech Carilion School of Medicine, Roanoke, VA; T. Michael O'Shea, Wake Forest Baptist Medical Center, Winston Salem, NC; Ian M. Paul, Penn State College of Medicine, Hershey, PA; John van den Anker, George Washington University School of Medicine and Health, Washington, DC; Kelly Wade, Children's Hospital of Philadelphia, Philadelphia, PA; Thomas J. Walsh, Weill Cornell Medical College of Cornell University, New York, NY.

• References

• 1 Alsayyed B. Rifampin. Pediatr Rev 2004; 25: 216-217
  CrossrefPubMedGoogle Scholar
• 2 Shama A, Patole SK, Whitehall JS. Intravenous rifampicin in neonates with persistent staphylococcal bacteraemia. Acta Paediatr 2002; 91 (6) 670-673
  CrossrefPubMedGoogle Scholar
• 3 Soraisham AS, Al-Hindi MY. Intravenous rifampicin for persistent staphylococcal bacteremia in premature infants. Pediatr Int 2008; 50 (1) 124-126
  CrossrefPubMedGoogle Scholar
• 4 van der Lugt NM, Steggerda SJ, Walther FJ. Use of rifampin in persistent coagulase negative staphylococcal bacteremia in neonates. BMC Pediatr 2010; 10: 84
  CrossrefPubMedGoogle Scholar
• 5 Tan TQ, Mason Jr EO, Ou CN, Kaplan SL. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother 1993; 37 (11) 2401-2406
  CrossrefPubMedGoogle Scholar
• 6 Bayston R. Hydrocephalus shunt infections. J Antimicrob Chemother 1994; 34 (Suppl A): 75-84
  CrossrefPubMedGoogle Scholar
• 7 Forward KR, Fewer HD, Stiver HG. Cerebrospinal fluid shunt infections. A review of 35 infections in 32 patients. J Neurosurg 1983; 59 (3) 389-394
  CrossrefPubMedGoogle Scholar
• 8 Gombert ME, Landesman SH, Corrado ML, Stein SC, Melvin ET, Cummings M. Vancomycin and rifampin therapy for Staphylococcus epidermidis meningitis associated with CSF shunts: report of three cases. J Neurosurg 1981; 55 (4) 633-636
  CrossrefPubMedGoogle Scholar
• 9 McGirt MJ, Zaas A, Fuchs HE, George TM, Kaye K, Sexton DJ. Risk factors for pediatric ventriculoperitoneal shunt infection and predictors of infectious pathogens. Clin Infect Dis 2003; 36 (7) 858-862
  CrossrefPubMedGoogle Scholar
• 10 Chapman RL, Faix RG. Persistent bacteremia and outcome in late onset infection among infants in a neonatal intensive care unit. Pediatr Infect Dis J 2003; 22 (1) 17-21
  CrossrefPubMedGoogle Scholar
• 11 O'Brien RJ, Long MW, Cross FS, Lyle MA, Snider Jr DE. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis. Pediatrics 1983; 72 (4) 491-499
  PubMedGoogle Scholar
• 12 Rifadin IV. Rifampin for injection [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2013
  Google Scholar
• 13 Bliziotis IA, Ntziora F, Lawrence KR, Falagas ME. Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials. Eur J Clin Microbiol Infect Dis 2007; 26 (12) 849-856
  CrossrefPubMedGoogle Scholar
• 14 Fortunov RM, Hulten KG, Hammerman WA, Mason Jr EO, Kaplan SL. Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates. Pediatrics 2006; 118 (3) 874-881
  CrossrefPubMedGoogle Scholar
• 15 Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin Infect Dis 2009; 49 (1) 65-71
  CrossrefPubMedGoogle Scholar
• 16 Borghesi A, Stronati M. Strategies for the prevention of hospital-acquired infections in the neonatal intensive care unit. J Hosp Infect 2008; 68 (4) 293-300
  CrossrefPubMedGoogle Scholar
• 17 Li S, Bizzarro MJ. Prevention of central line associated bloodstream infections in critical care units. Curr Opin Pediatr 2011; 23 (1) 85-90
  CrossrefPubMedGoogle Scholar
• 18 Schulman J, Stricof R, Stevens TP , et al; New York State Regional Perinatal Care Centers. Statewide NICU central-line-associated bloodstream infection rates decline after bundles and checklists. Pediatrics 2011; 127 (3) 436-444
  CrossrefPubMedGoogle Scholar
• 19 Moyer V, Freese DK, Whitington PF , et al; North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39 (2) 115-128
  CrossrefPubMedGoogle Scholar
• 20 Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983; 5 (Suppl. 03) S440-S450
  CrossrefPubMedGoogle Scholar
• 21 Lee CH, Lee CJ. Thrombocytopenia—a rare but potentially serious side effect of initial daily and interrupted use of rifampicin. Chest 1989; 96 (1) 202-203
  CrossrefPubMedGoogle Scholar
• 22 Mathur NB, Agarwal HS, Maria A. Acute renal failure in neonatal sepsis. Indian J Pediatr 2006; 73 (6) 499-502
  CrossrefPubMedGoogle Scholar
• 23 Agras PI, Tarcan A, Baskin E, Cengiz N, Gürakan B, Saatci U. Acute renal failure in the neonatal period. Ren Fail 2004; 26 (3) 305-309
  CrossrefPubMedGoogle Scholar
• 24 Stapleton FB, Jones DP, Green RS. Acute renal failure in neonates: incidence, etiology and outcome. Pediatr Nephrol 1987; 1 (3) 314-320
  CrossrefPubMedGoogle Scholar